Table 2.
Distribution of individuals with diagnosis of metabolic syndrome (MetS). Values are number of subjects (%)
| BPT | BPT+AM | Total | ||||
|---|---|---|---|---|---|---|
| MetS+ | MetS− | MetS+ | MetS− | MetS+ | MetS− | |
| Baseline | 14 (25.0) | 42 (75.0) | 16 (29.6) | 38 (70.4) | 30 (27.2) | 80 (72.8) |
| 3 months | 10 (17.9) | 46 (82.1) | 6 (11.1) | 48 (88.9)c | 16 (14.5) | 94 (85.5)a |
| 6 months | 11 (19.6) | 45 (80.4) | 7 (13.0)c | 47 (87.0)d | 19 (17.3) | 91 (82.3)b |
| 12 months | 17 (30.4) | 39 (69.6) | 8 (14.8) | 46 (85.2)e , # | 25 (21.8) | 85 (78.2) |
MetS+, patients with diagnosis of metabolic syndrome; MetS‐, patients without diagnosis of metabolic syndrome and see Table 1.
Based on intention‐to‐treat analysis. p‐values in comparison with baseline; a p = .007, b p = .017, c p = .013, d p = .022, e p = .039, (McNemar's test, p value ≤.017 was considered statistical significant, to correct for three pairwise comparisons). # p = .052 (chi‐square test) between BPT and BPT+AB groups. Diagnosis of metabolic syndrome: presence of central obesity (waist circumference ≥102 cm in men or ≥88 cm in women) and ≥2 of the following parameters: triglycerides ≥1.7 mmol/L, HDL‐cholesterol <1.03 mmol/L in men or <1.29 mmol/L in women, blood pressure ≥130/85 mm Hg, fasting glucose ≥5.6 mmol/L.